Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11β‐HSD1 Inhibitor, in Healthy Young and Elderly Subjects

Abstract

Inhibition of the enzyme 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) represents a potential mechanism for improving pain conditions. ASP3662 is a potent and selective inhibitor of 11β‐HSD1. Two Phase I clinical studies were conducted to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of single and multiple ascending doses of ASP3662 in healthy young and elderly non‐Japanese and young Japanese subjects. Nonlinear, more than dose proportional PK were observed for ASP3662 after single‐dose administration, particularly at lower doses (≤6 mg); the PK at steady‐state were dose proportional, although the time to ASP3662 steady‐state was dose dependent at lower doses (≤2 mg). Similar PK were observed between young Japanese, young non‐Japanese, and elderly non‐Japanese subjects. Specific inhibition of 11β‐HSD1 occurred after both single and multiple doses of ASP3662. A marked dissociation between pharmacokinetics and pharmacodynamics was observed after single, but not multiple doses of ASP3662. ASP3662 was generally safe and well tolerated.

This article is protected by copyright. All rights reserved.

http://bit.ly/2tfiT70